From Patient Selection to Future Therapies: JAK Inhibitors in Alopecia Areata

In the final episode with Dr. Mostaghimi, 'From Patient Selection to Future Therapies: JAK Inhibitors in Alopecia Areata,' the panelist explored the following critical questions:

How are you deciding on patient selection when using the different JAK inhibitors?

Which factors make you choose a. baricitinib, b. ritlecitinib, or c. deuruxolitinib?

What is your approach to switching between Janus kinase (JAK) inhibitors in alopecia areata (AA) and what is your most common switch?

Which additional data would you like to see from JAK inhibitors in the future and how do you foresee the therapeutic landscape for alopecia areata evolving over the next 5 years?

The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib preferred for adolescents aged 12 to 17 and patients with baseline dyslipidemia, and deuruxolitinib reserved for those seeking faster and more robust hair regrowth or who have not responded adequately to another JAK inhibitor. Dr. Mostaghimi emphasized that switching between JAK inhibitors — unlike switching between biologics — is clinically reasonable regardless of mechanism, as individual differences in drug metabolism may explain differential responses across agents, and that clinicians should allow 6 to 9 months before concluding a therapy is ineffective. Looking ahead, he identified key data gaps including long-term safety, durability of response, withdrawal outcomes, and real-world combination therapy data, while also expressing optimism about emerging topical therapies for mild-to-moderate AA and the potential development of targeted biologic options with more favorable safety profiles.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Insights series on alopecia areata. Please subscribe to our newsletter for information on upcoming video series and check out the rest of the videos in this series.